Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30, 2013.

Recent Corporate Highlights

  • Completed financing that generated net proceeds of $53.0 million
  • Strengthened our world-class precision medicine team with addition of Isan Chen to the position of chief medical and development officer
  • Progressed new formulations for MGCD265 with a goal of initiating dose expansion cohorts in selected patient populations in the first quarter of 2014
  • Initiated development plans for mocetinostat in patients with myelodysplastic syndrome, with a dose confirmation study expected to begin this year and plans to finalize discussions and obtain a special protocol assessment from the FDA for the design of a Phase III trial in the first half of 2014
  • "This has been a year of great progress for Mirati, we completed a successful financing ($53.0 million), built out an extremely accomplished precision medicine team and restructured the corporation, which will allow us to aggressively advance our oncology pipeline," said Dr. Charles Baum, president and CEO of Mirati. "In 2014, we will use the foundation we have built to achieve key milestones in each of our programs. By mid-2014 we plan to have confirmation of clinical activity for MGCD265, our kinase inhibitor program targeting Met, Axl and VEGFR, in selected solid tumor patients with high unmet need and potential accelerated approval registration paths. We also plan to initiate a Phase 1 study with MGCD516, our second multi-target kinase inhibitor program focused on Trk, RET, DDR and EphRs, in cancer patients by mid-2014 and to enter further expansion studies in selected tumor types by the end of 2014. We will complete discussions with the FDA to finalize our SPA for the design of a Phase 3 registration trial for mocetinostat in patients with myelodysplastic syndrome. This trial could be started by the second half of 2014."

    Third Quarter and Nine Months Ended September 30, 2013 Financial Results Cash, cash equivalents, marketable securities and restricted cash totaled $15.3 million as of September 30, 2013 compared to $37.3 million on December 31, 2012. The cash does not include the $53.0 million in net proceeds from the public offering of 3.25 million shares of the Company's common stock, which closed on October 29, 2013. The Company believes that with the recent financing it has sufficient financial resources to carry forward its current clinical development and operating plans through the end of 2015.

    Net research and development expenditures for the third quarter of 2013 were $5.5 million, $1.2 million higher than the third quarter of 2012. The higher expenses primarily reflect increased costs for mocetinostat and MGCD516. Net research and development expenditures were $15.5 million for the first nine months of 2013, compared to $10.1 million for the same period in 2012. Increases were primarily due to the factors listed above as well as increased costs for MGCD265, costs associated with organizational changes implemented in 2013 and a reduction in investment tax credits versus the prior year.

    General and administrative expenses in the third quarter of 2013 were $3.7 million, $2.0 million higher than in the third quarter of 2012. General and administrative expenses were $8.6 million in the first nine months, compared to $4.0 million for the same period in 2012. The increase primarily reflects higher share-based compensation costs and costs associated with the recent corporate reorganization and associated management changes.

    Other expense, net in the third quarter of 2013 was $20.1 million compared to other income, net of $34,000 for the same period in 2012. Other expense, net in the first nine months of 2013 was a $17.4 million compared to other income, net of $172,000 for the same period in 2012. The net expense for both periods of 2013 primarily reflects expense arising from the change in fair value of our warrant liability.

    Net loss and comprehensive loss for the third quarter ended September 30, 2013 was $29.4 million, or $2.95 per share, compared to net loss and comprehensive loss of $5.9 million, or $0.93 per share, for the same period last year. Net loss and comprehensive loss for the first nine months of 2013 was $41.6 million, or $4.18 per share, compared to net loss and comprehensive loss of $14.0 million, or $2.20 per share, for the same period in 2012.

    About Mirati Therapeutics
    Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates. More information is available at

    Forward Looking Statements
    Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Mirati and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "intend", "plan", "anticipate", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements regarding the potential for accelerated approval path for MGCD265, ability to secure a partner for the mocetinostat program, and the ability to obtain an SPA from the FDA.

    Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Mirati will be able to obtain financing when needed or on favorable terms, and other risks described in Mirati's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.

     Mirati Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(In thousands except for share and per share amounts)

    (Unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012ExpensesResearch and development, net$




    10,105General and administrative3,7101,7178,6164,019Total operating expenses9, 2025,96624,09314,124Loss from operations(9,202)(5,966)(24,093)(14,124)Other (expense) income, net(20,141)34(17,418)172Loss before income taxes(29,343)(5,932)(41,511)(13,952)Income tax expense551411527Net loss and comprehensive loss$




    (13,979)Basic and diluted net loss per share$




    (2.20)Weighted average number of shares used in computing net loss per share, basic and diluted9,957,8966,361,0939,957,7926,359,216 

    Mirati Therapeutics, Inc.Condensed Consolidated Balance sheets(In thousands)September 30,2013December 31,2012Assets(Unaudited)Current assetsCash, cash equivalents and marketable securities$


    36,983Restricted cash equivalents and marketable securities291302Interest and other receivables186507Other current assets1,5101,537Total current assets17,02139,329Other long-term assets553139Property and equipment, net427333Total assets$


    39,801Liabilities and Stockholders' Equity (Deficit)Current liabilitiesAccounts payable and accrued liabilities6,6155,340Share-based compensation liability2,144—Warrant liability32,803—Total current liabilities41,5625,340Other liability—45Total liabilities41, 5625,385Total stockholders' equity (deficit)(23,561)34,416Total liabilities and stockholders' equity (deficit)$

    SOURCE Mirati Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Mirati Therapeutics Prices Public Offering Of Common Stock
    2. Sorrento Therapeutics Adopts Stockholder Rights Plan
    3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
    5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
    6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
    8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
    9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
    11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
    Post Your Comments:
    (Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
    (Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
    (Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
    Breaking Medicine Technology:
    (Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South Austin is treating ... Hours a day. , The Emergency Room opened early March, making ... four months now and things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s ...
    (Date:7/24/2017)... MO (PRWEB) , ... July 24, 2017 , ... ... acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of Saint ... basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley ...
    (Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has ... Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The ... facilitate the development of a hub and spoke model for opioid treatment in ...
    (Date:7/24/2017)... ... July 24, 2017 , ... ... in scholarship awards to be awarded annually to and divided between two full-time ... in bringing awareness to Amazonian plant medicine. To apply for the scholarship, students ...
    (Date:7/24/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... to expand its solution to help government contractors more quickly and cost-effectively comply ... to address the authentication requirements within NIST SP800-171, but no matter how you ...
    Breaking Medicine News(10 mins):